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The use of griseofulvin as a systemic anti-
dermatophyte in humans is well established; how
ever, only limited data are available relating to the
efficiency and mode of its absorption. In an in-
vestigation of the absorption of griseofulvin in
rats after oral administration, it was observed by
Bedford et al. (1) that maximum blood levels were
attained within four hours. They also found that
tissue concentrations paralleled blood levels and
that the absorption appeared to be self-limiting.
After 24 hours, they were able to recover 16% of
the administered dose in the feces as intact drug.
When the feces and the entire alimentary tract
were extracted, Davis (2) recovered 91% and
55% of the oral dose in rats after 4 and 24 hours,
respectively.
Crounse (3) reported that blood levels of
griseofulvin were variable in human subjects and
could be enhanced when the drug was adminis-
tered in conjunction with high fat meals. Re con-
cluded that inadequate absorption may be one of
the mechanisms of clinical failure with ordinary
therapeutic doses of griseofulvin. Other investi-
gators (4, 5, 6) have also observed irregular blood
levels and excretion rates after oral administra-
tion to humans. Riegelman (4) has been able to
demonstrate greatly enhanced absorption by
using a supersaturated solution of the drug in
polyethylene glycol 400.
Surfactant Effect. It has been reported in the
literature that surfactants promote the absorption
of iron (7), spironolactone (8) and fat soluble sub-
stances (9) from the gastrointestinal tract. Kraml
et at. (10) found that there was no increase of
serum blood levels in rats when Perminal BXN
(butylated sodium naphthalene sulfonate) was
added to an aqueous suspension of griseofulvin.
However, Duncan et at. (11) observed that the
same surface active agent in aqueous suspension
Received for publication January 11, 1963.
* From McNeil Laboratories, Inc., Fort Wash-
ington, Pa. and the Department of Dermatology,
University of Pennsylvania School of Medicine,
Philadelphia, Pa. Address of Dr. John R. Marvel
now Johnson Research Center, New Brunswick,
New Jersey.
gave rise to higher blood levels. They found that
the method of incorporating the surfactant into
the preparation had a pronounced effect on the
attained blood levels. The addition of Perminal
BXN to tablets had no significant effect upon
human blood levels.
Particle Size Effect. It has been shown by many
investigators that particle size has a pronounced
effect upon the biological activity of certain
therapeutic agents. Douglas et at. (12) have
demonstrated that in nematode infections of
sheep, the particle size of phenothiazine is an
important factor in determining its anthelminthic
activity. He found that phenothiazine, having a
particle diameter of 140 microns or larger, was
ineffective. However, drug with a mean particle
diameter between 40 and 50 microns was 70%
effective and drug with a mean particle diameter
between 1 and 2 microns was 95% effective.
Investigations have shown that sulfadimethoxine
(13), sulfadiazine (14), phenolphthalein (15) and
sulfur (16) are more rapidly absorbed when ad-
ministered in a microcrystalline dosage form.
Griseofulvin exhibits the low water solubility
of approximately 1 mgm per 100 ml. This physi-
cal property may have a pronounced effect upon
the availability of the drug for absorption and
may be responsible for the self-limiting factor re-
ported by Bedford (1). Since Riegclman found in
humans that absorption could be enhanced when
the drug was given in solution, we have investi-
gated methods to enhance the drug's solubility in
water and to modify the physical properties to
promote availability for absorption. The two
principal approaches pursued were reduction of
particle size and solubilization by surfactants.
We have attempted to study griscofulvin blood
levels in rats, guinea pigs and human volunteers
following the oral administration of the drug in
solution, in different particle sizes and with the
co-administration of a surfactant.t
t The authors are grateful for the cooperation
of the volunteer subjects at Moyamensing Prison,
Philadelphia, Pennsylvania
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METHODS
Solubility.—The aqueous solubility of griseo-
fulvin with and without sodium lauryl sulfate
(SLS) were determined in a water bath at 30
0.10. Our findings are shown in Table I
Biological Tests—Male rats were given identical
TABLE I
Solubilization of griseofulvin by SLS in
water at 300
% SLS Griseofulvin (mg %)
0
0.25
0.5
1.0
2.0
1
17
41
91
171
TABLE II
Comparison of griseofulvin plasma levels
following the oral administration of a
solution and a suspension to rats
Dosage Form
Administered
Dose
(mg/
Kg)
Plasma Levels in mcg/ml
2 4 6 24
Hrs Hrs Hrs Hrs
Polyethylene glycol 50 2.4 2.2 2.3 0
400 Solution,
0.5%
Aqueous Suspension 50 1.3 0.7 0.7 0
0.5%
TABLE III
Comparison of griseofulvin microbiological activity
in blood following the oral administration of
different particle sizes of drug with and
without SLS to guinea pjg5*
Preparation
Administered
Dose
(mg/Kg)
Average
Blood Level
(mcg/ml of
activity)
Griseofulvin SSA 0.41
M2/Gm
Griseofulvin SSA 0.41
M2/Gm + SLS
Griseofulvin SSA 1.0
M2/Gm
Griseofulvin SSA 1.0
MZ/Gm + SLS
60
60 + 12
60
60 + 12
2.22
3.26
4.28
3.87
* These biological studies were conducted by
Dr. E. R. L. Gaughran.
oral doses of griseofulvin as a solution in poly-
ethylene glycol 400 or as an aqueous suspension.
Blood samples were obtained by direct cardiac
puncture from anesthetized animals. Each speci-
men for analysis represented the pooled blood
from three rats. Plasma levels were determined
according to the spectrophotofluorometric method
of Bedford et al. (17). The results obtained are
reported in Table II.
Blood levels were determined in groups of three
male guinea pigs following single oral doses of
griseofulvin suspensions of two different particle
sizes, with and without SLS. Six hours post ad-
ministration, 2 ml blood samples were withdrawn
and immediately assayed against Trichophyton
mentagrophytes colonies of a reproducible size.
Standard curves were simultaneously obtained
by adding known amounts of griseofulvin to 2 ml
samples of control blood. After five days incuba-
tion, cultures were compared. The results are re-
ported as griseofulvin activity in Table III.
Human Protocol .—The methods of administer-
ing the drug and collecting samples were as fol-
lows.
In the studies with single oral doses, 12 healthy
fasting male and female subj ects were given four
250 mg tablets of one kind of griseofulvin (regular
or microcrystalline*, with or without sodium
lauryl sulfate) at 8 am. Blood samples were drawn
into heparinized syringes at 0, 1, 4, 8, 24 and 48
hours after dosing. Each subject received all four
kinds of griseofulvin at the same dose, at weekly
intervals, and the order of administration was
randomized by a Latin Square design.
When multiple doses were administered, groups
of 6 or 12 healthy male volunteers were given a
125 mg or 250 mg tablet of one form of griseofulvin
at 8 am., noon, 4 p.m. and 8 p.m. each day for a
week (or for 29 days in the last study). Blood
samples were obtained at 8 am, on the first day
and at 4p.m. on days 1—7. In the week-long studies,
half of the subjects in the first week were always
given one form of griseofulvin, the other half
another form of the drug. An interval of a week
without drug was permitted to elapse. The sub-jects were then crossed over to the second form
of the drug in the third week. In the long-term
crossover study, two weeks without drug inter-
vened between the 29-day periods on drug. Blood
samples in this study were obtained at 8 am. on
the first day and at 4 p.m. on days 1, 2, 3, 4, 5, 8,
15, 22 and 29.
In this and all other studies, the plasma was
removed after centrifugation and frozen. Dupli-
cate assays of all samples on one subject were run
on the same day.
Assay—Plasma levels of griseofulvin were de-
termined by the spectrophotofluorometric method
of Bedford et al. (17). An Aminco-Bowman spectro-
photofluorometer coupled to an X-Y Electro
* Regular griseofulvin as Grifulvin® McNeil
and microcystalline griseofulvin as Grifulvin V®
McNeil.
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Instruments recorder was used. It has been re-
ported by Child et al. (18) and Marvel (Crounse,
3) that certain drugs in common usage, such as
aspirin, interfere with the fluorometric analysis of
griseofulvin. To ensure that all hydroalcoholic
plasma extracts were contaminant-free, at least
one sample for each plasma specimen was scanned
between the analyzing wavelengths of 200 and 800
millimicrons. (For comparison with the English
workers (1, 2, 18, 19 and 20), it should be noted
that plasma levels by this assay are 40% higher
than whole blood levels.)
Particle Size.—Griseofulvin mean particle di-
ameters were determined using a Fisher sub-sieve
sizer and specific surface areas were calculated
therefrom.
GRISEOFULVIN PLASMA LEVELS 199
2,5
2,0
1.5
1.0
0. 5
2, 5
2, 0
1,5
1,0
0, 5
0
DAY
Fxa. 1. A comparison of the effect of particle size and sodium lauryl sulfate (S.L.S.) on griseofulvin
plasma levels after the administration of a single oral dose of one gram. 0 S.S.A. 0.41 M2/Gm. A S.S.A.
0.41 M2/Gm. plus S.L.S. (200 mg), average for twelve subjects. • S.S.A. 1.0 M2/Gm. A S.S.A. 1.0 M2/
Gm. plus S.L.S. (200 mg.) average for twelve subjects.
FIG. 2. A comparison of the effect of sodium lauryl sulfate (S.L.S.) on griseofulvin plasma levels during
the administration of repeated doses. 0 S.S.A. 0.41 M2/Gm., 250 mg. tablets four times a day, average
for five subjects. A S.S.A. 0.41 M2/Gm., 250 mg. plus S.L.S. 50 mg. tablets four times a day, average for
five subjects.
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RESULTS AND DISCUSSION
Sodium lauryl sulfate was chosen for this study
because of its safety and solubilizing properties.
The effect of SLS is to markedly increase the
aqueous solubility of griscofulvin, as shown in
Table I.
As shown in Table II, when the identical dose
in the same volume of vehicle was administered
orally to rats as a solution in polyethylene glycol
400 or as an aqueous suspension, higher plasma
levels were obtained with the solution. The data
obtained in our laboratories is in agreement with
the work of Riegelman (4), and gives further
credence to the fact that incomplete absorption
occurs in rats after oral administration of the
drug.
Table III shows the enhancing effect of re-
duced particle size and of SLS on griseofulvin
microbiologic activity following oral administra-
tion to guinea pigs.
A comparison of the effect of SLS and of vary-
ing particle sizes in a griscofulvin tablet on plasma
levels in humans was made and is reported in Fig.
1. The results indicate that either SLS or reduc-
tion of particle size will improve the plasma levels
obtained with S.S.A. 0.41 M1/Gm griseofulvin.
Since SLS increased griseofulvin levels in
single oral doses in both guinea pigs and humans,
a comparison was made using multiple daily doses
over a prolonged period of time as shown in Fig.
2. Contrary to expectations, no enhancement
occurred. Apparently, multiple dosing improved
the efficiency of absorption as much as the sur-
factant could. Atkinson et al. (19) in studying dos-
age regimens have found that divided daily dos-
age results in higher blood levels than single daily
doses. Consequently, one must design experi-
ments so that the information obtained will be
valid when applied to clinical programs. Caution
must be used in interpreting data from single
dose experiments.
Other investigators, using single oral doses,
have reported on the effect of particle size on
griseofulvin blood levels (11, 20, 21). As men-
tioned previously, using griseofulvin of large
particle size, Atkinson et al. (19) obtained higher
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Fio. 3. A comparison of the effect of particle size on griscofulvin plasma levels in man during the ad-
ministration of tablets. 0 S.S.A. 0.41 M1/Gm., 250 mg. four times a day, average for eleven subjects.
• S.S.A. 1.46 M1/Gm., 250 mg. four times a day average for eleven subjects.
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TABLE IV
Plasma griseofulvin levels in mcg/ml in. man on repeated oral doses of 250 my tablets
four times a day using 8.S.A. 0.41 M2/Gm material
Subject
Day __ Avg. S.D.
1
____
1 0.62 1.50 1.42 0.57 1.62 0.73 0.83 1.16 1.22 0.97 1.41 1.12 0.41
0.61 1.51 1.27 0.57 2.07 0.75 0.70 1.42 — 1.27 1.33
2 — 2.05 1.68 1.15 3.20 1.42 1.43 2.34 2.60 2.23 3.35 2.14 0.72
— 2.21 1.62 1.02 2.82 — 1.47 2.82 2.48 1.65 3.20
3 2.37 2.02 2.16 2.48 3.35 3.12 1.40 1.70 2.52 2.97 3.05 2.35 0.58
2.37 1.93 1.77 1.92 2.60 3.05 1.18 1.76 2.55 — 3.02
4 2.94 1.80 2.60 1.67 3.08 2.97 0.86 1.70 2.45 3.54 2.90 2.29 0.76
2.94 1.63 2.21 1.55 3.08 — 0.86 1.57 2.52 2.45 2.86
5 1.70 1.62 2.51 — 3.27 3.20 0.80 1.61 2.52 — 3.42 2.23 0.84
1.45 1.56 — — 2.67 — 1.22 2.71 3.27
8 1.47 1.73 2.02 1.30 3.08 1.76 1.17 1.20 2.41 — 2.97 1.90 0.67
1.45 1.73 1.95 1.24 2.93 — 1.05 1.18 2.45 — 2.93
15 1.82 1.66 1.92 1.79 2.52 2.71 1.66 2.16 2.52 2.16 3.11 2.21 0.47
1,78 1.68 2.06 — 2.90 2.49 1.76 2.07 2.18 3.20
22 1.46 1.86 1.46 1.41 2.31 2.13 1.27 2.15 2.90 2.48 2.56 2.02 0.49
1.45 1.72 1.58 1.91 2.32 2.07 1.31 2.21 2.82 2.32 2.71
29 1.42 1.82 1.91 2.01 2.26 2.93 1.53 1.13 2.71 1.52 1.51 1.89 0.53
1.42 1.82 1.92 2.01 2.31 2.75 — 1.17 2.71 1.32 1.49
TABLE V
Plasma griseofulvin levels in mcg/ml in man on repeated oral doses of 125 my tablets
four times a day using SJS.A. 1.45 M2/Gm material
Subject
Day ___- __________________ _-__ Avg. S.D.
1 2 3 4 5 6 7 8 9 10 11
1 1.23 1.33 0.70 0.95 1.10 1.00 0.76 1.47 0.53 0.61 0.96 1.01 0.17
1.21 1.40 0.76 0.83 0.97 1.12 0.85 1.70 0.70 0.97
2 — 2.60 1.90 2.37 1.87 2.06 1.61 1.20 1.80 2.00 1.87 1.84 0.39
— 2.37 1.64 2.32 1.85 — 1.42 1.11 1.22 1.51 2.16
3 1.45 3.05 1.56 1.08 2.26 3.07 2.23 1.83 1.56 1.75 2.00 2.00 0.56
1.50 2.41 1.51 1.11 2.15 3.05 1.77 2.31 2.06 — 2.25
4 1.64 2.41 1.71 1.27 1.65 3.01 1.57 1.87 1.87 1.87 1.93 1.85 0.42
1.64 2.71 1.85 1.25 1.82 — 1.50 1.93 1.82 1.71 1.90
5 1.49 2.60 1.68 — 2.05 3.80 1.64 2.00 1.83 — 2.45 2.06 0.59
1.49 2.30 — — 2.00 — 1.58 1.65 — 2.37
8 1.76 2.09 1.68 1.32 1.65 2.47 1.27 1.46 1.47 — 1.47 1.62 0.28
1.47 2.07 1.62 1.28 1.60 — 1.57 1.66 1.37 — 1.45
15 1.93 1.42 2.05 — 1.68 2.41 1.02 1.72 1.59 1.66 2.05 1.77 0.37
2.22 1.45 1.66 1.54 1.61 2.67 1.48 1.57 — 1.71 1.98
22 1.28 1.50 2.67 0.52 1.90 2.22 1.62 1.42 1.87 1.47 2.10 1.71 0.58
1.32 1.60 2.90 0.45 1.77 2.67 1.56 1.51 1.80 1.43 2.00
29 1.52 2.22 2.10 1.74 1.45 1.97 1.40 1.40 1.90 1.02 2.01 1.70 0.37
1.42 2.11 2.37 1.64 1.45 2.05 — 1.35 1.77 0.96 1.87
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blood levels with divided daily doses than with
single daily doses. Having failed to find plasma
level enhancement with surfactants when admin-
istered in a prolonged, divided dose schedule, we
felt it imperative to study microcrystalline
griseofulvin under multiple dose conditions for a
prolonged period of time.
The effect of particle size on griseofulvin plasma
levels was studied in humans as described in the
protocol. The results are recorded in Fig. 3 and
show that the microcrystalline material gives
levels that arc between 35 and 50% higher than
the regular material when given four times a day
as tablets for a week.
Half-doses of microcrystalline griscofulvin
were compared with full doses of regular grisco-
fulvin in a similar manner for one month. The
results arc recorded in Tables IV and V. The
averages show no significant differences except
on day four, when analyzed by Student's "t"
test. Fig. 4 represents these results graphically.
We may conclude that significantly higher
plasma levels arc maintained using griscofulvin of
greater surface area under clinical conditions.
Plasma levels approximately equal to a full dose
of standard griscofulvin can be maintained for a
prolonged period of time using half-doses of
microcrystalline griscofulvin.
SUMMARY AND CONCLUSIONS
The administration to guinea pigs and to
human subjects of a single oral dose of regular
griscofulvin with sodium lauryl Sulfate (SLS)
gave higher griseofulvin plasma levels than the
drug lone. However, in man, when the same daily
dose was divided and given each day for a week,
the SLS had no enhancing effect on the at-
tained plasma levels.
An increase in griseofulvin plasma levels in
guinea pigs and human subjects was found when
the particle size of the griscofulvin was reduced.
Significantly higher levels were maintained for a
week when one gram daily divided doses of
griscofulvin S.S.A. 1.46 M2/Gm were compared
with griseofulvin S.S.A. 0.41 M2/Gm. No sig-
nificant difference could be found, except on day
four, when half-doses of the microcrystalline
griscofulvin were compared similarly with full
doses of regular griseofulvin for a month.
Caution must be used in interpreting data from
single dose studies. Experiments need to be
designed so that the information obtained will be
valid when applied to clinical use.
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